ERBB2 and breast carcinoma: In these exceptional responders, the risk of breast cancer recurrence is low with associated excellent 5‐year relapse free survival of 95% and 94% in patients with HER2+ and Triple Negative breast cancers, respectively.[11] These findings argue against the need for definitive surgery and directly challenge the current paradigm of surgical resection established for solid tumors.